Pill-in-the-Pocket Dosing for Atrial Fibrillation

Introduction to Pill-in-the-Pocket Therapy

The European Society of Cardiology recommends self-administered cardioversion of paroxysmal atrial fibrillation using flecainide 200-300 mg or propafenone 450-600 mg as a single oral dose, but only after safety has been confirmed in a monitored hospital setting first 1, 2

The American Heart Association suggests a single oral dose of flecainide: 200-300 mg for cardioversion of paroxysmal atrial fibrillation 1, 2, 3
The American College of Cardiology recommends a single oral dose of propafenone: 450-600 mg for cardioversion of paroxysmal atrial fibrillation 1, 2, 3
No follow-up dose is needed for either flecainide or propafenone 1, 4
The mean time to conversion is approximately 2 hours for both flecainide and propafenone 5, 6

The European Society of Cardiology requires administration of the first dose in a monitored hospital setting to establish safety 1, 2, 5, 6
Pre-treatment with a beta-blocker or non-dihydropyridine calcium channel blocker at least 30 minutes before the Class IC agent is necessary to prevent rapid 1:1 AV conduction if atrial flutter develops 2, 5, 6, 3

The American College of Cardiology states that patients with any coronary artery disease (CAD) of any severity should not receive pill-in-the-pocket Class IC drugs 2, 3
Significant structural heart disease is an absolute contraindication for pill-in-the-pocket therapy 1, 2, 3
Left ventricular dysfunction or reduced ejection fraction is a contraindication for pill-in-the-pocket therapy 2, 3
Sinus or AV node dysfunction, bundle branch block, QT interval prolongation, and Brugada syndrome are all absolute contraindications for pill-in-the-pocket therapy 5, 6

The European Society of Cardiology reports that pill-in-the-pocket therapy achieves successful conversion in approximately 94% of episodes 5, 6
Pill-in-the-pocket therapy reduces emergency department visits and hospitalizations 5, 6
The American Heart Association notes that pill-in-the-pocket therapy provides patient autonomy and reassurance for selected individuals 1, 4